V8 Peptides — Engineered Performance
Research Library
AOD-9604 Purity: Disulfide Quality and COA Checks
AOD-9604Quality & Testing

AOD-9604 Purity: Disulfide Quality and COA Checks

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What should AOD-9604 quality testing cover? HPLC purity plus identity by mass, because AOD-9604 has an intramolecular disulfide that an area-percent figure cannot confirm. Check method, date and lot; consider counterions and water in the stated vial mass; avoid reducing agents. The V8 page lists at least 98% by HPLC and currently marks the certificate as in progress. Supplied for laboratory research use only.

Quality questions about AOD-9604 are more interesting than for most short peptides because the molecule has a feature that a plain linear sequence lacks: two cysteine residues joined by an intramolecular disulfide bond. That bond makes the molecule a small loop, and it means purity is not only a question of "is the main peak large" but also "is the bond formed correctly, and in the right place". This article explains what purity standards and quality tests mean for a disulfide-containing 16-residue peptide, what the V8 product page states, and which questions a laboratory should ask of any batch. It is a quality guide for laboratory researchers; it does not compare or name any other source, and no use outside a laboratory is described.

From the AOD-9604 product page: AOD-9604 is described as a C-terminal fragment of human growth hormone, hGH 176–191, with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, molecular formula C78H123N23O23S2, supplied as a lyophilized powder in a sealed clear glass 5 mg vial with a purity specification of at least 98% by HPLC. Storage is 2–8 °C, or −20 °C long term, protected from heat, moisture and light. At the time of writing, the product page marks the certificate of analysis as in progress, and that status shapes how the rest of this article should be applied.

What "at least 98% by HPLC" does and does not say

A reversed-phase HPLC purity figure is the area of the main peak expressed as a share of the total integrated peak area at one detection wavelength, usually in the low UV where the peptide bond absorbs. It is a useful screen for related impurities that elute separately. It does not report peptide content by weight, which also depends on water and counterions, and it cannot see impurities that do not absorb or that co-elute. A review of related impurities in peptide medicines describes the families that arise in solid-phase synthesis: deletion and truncation sequences, incompletely deprotected chains, racemized residues and side-chain modifications (D'Hondt et al., 2014), and any of these can sit under or beside the main peak depending on the method. A responsible reading therefore asks four things of a purity figure: which method, which wavelength, which date, and which lot.

The disulfide bond adds its own failure modes

For AOD-9604 the two cysteines in the sequence close the loop when oxidized. Three things can go wrong that an area-percent figure does not distinguish. Incomplete oxidation leaves a reduced, linear form with two free thiols. Intermolecular oxidation produces dimers, and larger oligomers, in which cysteines on different chains pair. And partial oxidation of the thioethers and thiols to sulfoxide-like or over-oxidized forms changes the mass. The product page notes that the molecule depends on an intact disulfide bond and advises keeping reducing agents out of the diluent unless the protocol calls for them; that is the practical consequence for handling, and it is why identity testing for this peptide is more than a retention-time match.

SpeciesMass relative to intact peptide (calculated)How it is typically distinguished
Intact peptide with one disulfideReference (average about 1,815 Da from the product-page formula)Mass spectrometry plus HPLC
Reduced, linear formAbout +2 Da (two added hydrogens)Mass spectrometry; shifts in HPLC retention; thiol-specific assay
DimerAbout twice the monomer minus hydrogens, depending on pairingMass spectrometry; size-based separation
Oxidized side-chain variantsIncrements of about +16 Da per added oxygenHigh-resolution mass spectrometry
Deletion or truncation productsLower mass by the missing residuesMass spectrometry; HPLC

The average molar mass computed from the product-page formula is about 1,815.1 g/mol and the monoisotopic mass about 1,813.86 Da. Those figures are calculated, not measured on any lot, and the one-mass-unit and two-mass-unit differences above are small relative to the molecular weight, which is why a mass spectrometer with adequate resolution matters. See HPLC vs mass spectrometry for how the two techniques complement each other.

Counterions, water and what the vial mass means

Lyophilized peptides are salts with variable water content. Trifluoroacetate is a common counterion after reversed-phase purification, and one cell-culture study reported that trifluoroacetate reduced proliferation in osteoblast and chondrocyte cultures at low concentrations (Cornish et al., 1999). The practical consequence is that "5 mg" on a label is the mass of the powder and should be regarded as an upper bound for peptide. The product page gives the arithmetic for stock solutions: adding 1 mL to a 5 mg vial gives 5 mg/mL, 2 mL gives 2.5 mg/mL and 2.5 mL gives 2 mg/mL, so that a 100 µL aliquot of the 2.5 mg/mL stock contains 250 µg of peptide. A lab that needs exact molarity should confirm concentration by amino-acid analysis or a validated UV method. The reconstitution calculator handles the nominal arithmetic and peptide reconstitution volume calculations explains each variable.

How the product is made, and what that predicts about impurities

Fmoc solid-phase peptide synthesis is the dominant approach, and a review of advances in the method documents its chemistry in detail (Behrendt et al., 2016). Chemical manufacture of peptide drugs at scale has been described for decades (Bray, 2003). For a disulfide-containing 16-mer, the process steps predict the impurity map: assembly gives deletions and truncations; cleavage can leave protecting-group adducts, with cysteine a sensitive position; oxidation gives monomer, dimer and mis-oxidized species; purification and drying give salt and water. A batch record that mentions the oxidation step and how its completion was checked says more about quality control than a purity number does.

Reading the certificate of analysis for this peptide

The product page lists documentation items: compound identity and sequence, measured HPLC purity, sequence or identity confirmation, batch or lot number, analytical test date, and supplied form and storage. Against those items, the table marks what each tells a laboratory about AOD-9604 specifically.

Document itemUseful for AOD-9604 if…Gap to close if it is absent
Identity and sequenceThe stated mass matches the formula C78H123N23O23S2 within instrument toleranceRun your own mass check
HPLC purityMethod, wavelength and chromatogram are provided, not just a numberAsk for the method; compare with a retained sample
Identity confirmationMethod named (for example mass spectrometry)Confirm disulfide status independently
Lot number and dateMatches the vial and is recentDo not apply a prior lot's data
Certificate statusPublished for your lotRegard purity and identity as unverified until published

The status line matters here. The product page currently marks the AOD-9604 certificate as in progress. A responsible record states exactly that: a purity specification exists, a lot-specific certificate had not been published when the page was read, and independent verification, if the experiment needs it, is the lab's to arrange. Once a certificate is published it appears on the COA page, and how to read a COA explains the fields. Related reading: AOD-9604 purity testing, understanding HPLC purity and third-party testing explained.

A receiving and retention routine

  • Match label to paperwork: compound name, 5 mg size and lot number.
  • Inspect the vial: sealed, intact stopper, a dry white cake or loose powder; see peptide vial appearance.
  • Record conditions: date received, packaging state and storage location; return to 2–8 °C, or −20 °C for the long term, away from heat, moisture and light.
  • Equilibrate before opening: let a cold vial reach room temperature so condensation does not form, as the product page advises.
  • Avoid reducing agents: keep them out of the diluent unless the protocol requires them, because they would open the disulfide.
  • Retain a portion: hold back a sealed vial or frozen aliquot for later re-testing, and aliquot reconstituted stock to limit freeze-thaw cycles.

What this guide does not claim

This article makes no statement about the biology of AOD-9604, about how any other source tests its material, or about any lot of V8 material. It describes the questions a quality record should answer for a disulfide-containing peptide. For sourcing context, see where to buy AOD-9604, and for the molecule's background, the AOD-9604 research overview. The product is sold for laboratory research use only; the catalogue is on the shop page.

Frequently asked questions

Why is purity harder to judge for AOD-9604 than for a linear peptide?

Because of the intramolecular disulfide bond between the two cysteines. An HPLC purity figure does not show whether the bond is formed, whether dimers are present or whether the molecule is oxidized elsewhere; mass spectrometry helps.

What does the V8 product page state about AOD-9604 quality?

A purity specification of at least 98% by HPLC, a 5 mg lyophilized vial, formula C78H123N23O23S2, storage at 2–8 °C or −20 °C long term, and a certificate status that is currently marked as in progress.

Is there a published certificate for AOD-9604 at V8?

At the time of writing the page marks the certificate as in progress. Regard identity and purity as unverified for a lot until a certificate for that lot is published, or verify independently.

What is the calculated mass of AOD-9604?

From the product-page formula, about 1,815.1 g/mol average and 1,813.86 Da monoisotopic. These are calculated values, not measurements of any lot.

How does a reduced or dimeric form show up?

A reduced form is about 2 Da heavier, a dimer is about twice the mass, and oxidized variants gain about 16 Da per oxygen. Mass spectrometry with adequate resolution separates them.

Why avoid reducing agents in the diluent?

The molecule depends on an intact disulfide bond, and reducing agents would open it. The product page advises keeping them out unless a protocol calls for them.

Does 5 mg on the label mean 5 mg of peptide?

It is the powder mass. Water and counterions are part of it, so regard it as an upper bound and confirm concentration if precision matters.

What is a reasonable stock concentration to prepare?

The arithmetic is mass divided by volume: 1 mL into 5 mg gives 5 mg/mL and 2 mL gives 2.5 mg/mL, as the product page states. Choose by the assay.

Why does counterion content matter?

Trifluoroacetate, a common counterion, was reported to reduce proliferation in osteoblast and chondrocyte cultures (Cornish et al., 1999), so it can matter in sensitive cell assays.

Is AOD-9604 sold for use outside the laboratory?

No. It is supplied strictly for laboratory research use only and is not intended for human or animal consumption.

Related reading: AOD-9604 Preclinical Literature: Study by Study, AOD-9604 Reconstitution Math and Rodent Study Parameters, AOD-9604 in Rodent Models: Obese Mice and Zucker Rats.

References

  1. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012
  2. Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.e779
  3. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836
  4. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2(7):587-593. doi:10.1038/nrd1133

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.